{"id":"W1542863370","doi":"10.1158/1538-7445.sabcs14-p4-15-08","title":"Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; La Cité Médicale","funders":"","keywords":"Lapatinib; Medicine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Neratinib; Oncology; Trastuzumab emtansine; Progressive disease; Anthracycline; Cancer; Breast cancer; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061032,0.00194746,0.001352962,0.0004508015,0.0003798204,0.0009731404,0.001252949,0.001307708,0.004947876],"category_scores_gemma":[0.0004877743,0.0005966753,0.000913502,0.0003296046,0.0008672077,0.0008065442,0.0003141764,0.003508121,0.001347083],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001016272,"about_ca_system_score_gemma":0.001814492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00263258,"about_ca_topic_score_gemma":0.004480595,"domain_scores_codex":[0.9997291,0.00008623488,0.00001464744,0.00005829587,0.00003776643,0.00007392504],"domain_scores_gemma":[0.9996126,0.00004324297,0.00005303355,0.00002924024,0.00003371847,0.0002281107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3208279,0.237352,0.006422496,0.001482065,0.001941634,0.0009659784,0.0006475233,0.006540044,0.2434146,0.0008574715,0.01688582,0.1626626],"study_design_scores_gemma":[0.237786,0.7253876,0.008923836,0.00004730095,0.0004284771,0.0006640067,0.00009361347,0.002187744,0.01813442,0.0002977003,0.005999931,0.00004929655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899049,0.001242496,0.000812847,0.0004317129,0.0001060731,0.002297355,0.001921738,0.0001921777,0.003090712],"genre_scores_gemma":[0.9740349,0.00202322,0.003232936,0.001047938,0.0001204692,0.002419063,0.006959809,0.00008804152,0.01007354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004947876,"threshold_uncertainty_score":0.01655227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1981755028695069,"score_gpt":0.4931715194821537,"score_spread":0.2949960166126468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}